Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study

RECOMMENDED

Asthma

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID

doi: 10.1016/S2213-2600(21)00124-7

AsthmaCOPD

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

Lancet Respir Med.

Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M

doi: 10.1016/

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma

N Engl J Med.

O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK

doi: 10.1056/NEJMoa1715274.

Asthma

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Eur Respir J.

Jorup C, Lythgoe D, Bisgaard H

doi: 10.1183/

RECOMMENDED

Asthma

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma

N Engl J Med.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M, Novel START Study Team.

doi: 10.1056/NEJMoa1901963.

RECOMMENDED

Asthma

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Asthma Allergy

Just J, Thonnelier C, Bourgoin-Heck M, Mala L, Molimard M, Humbert M, STELLAIR Investigators.

doi: 10.2147/JAA.S310888

RECOMMENDED

COPD

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

Respir Res.

Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K

doi: 10.1186/s12931-019-0972-7.

RECOMMENDED

Asthma

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Lancet.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R, PRACTICAL study team.

doi: 10.1016/S0140-6736(19)31948-8.

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines

Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J, Szépfalusi Z, Wantke F, Zacharasiewicz A, Studnicka M

Related content

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines